论文部分内容阅读
目的：为探讨西妥昔单抗在鼻咽癌中的作用,本研究初步观察西妥昔单抗联合放疗治疗晚期鼻咽癌患者的不良反应及近期疗效。方法：取我科收治的晚期鼻咽癌患者12例。西妥昔单抗与放疗同时使用,用法：西妥昔单抗第1周初始剂量为400mg/m2,以后每周维持剂量为250mg/m2,共8周。
西妥昔单抗联合放疗治疗进展期鼻咽癌的近期疗效观察
【摘 要】
：
目的：为探讨西妥昔单抗在鼻咽癌中的作用,本研究初步观察西妥昔单抗联合放疗治疗晚期鼻咽癌患者的不良反应及近期疗效。方法：取我科收治的晚期鼻咽癌患者12例。西妥昔单抗
【机 构】
：
长春 吉林省肿瘤医院放疗二科
【出 处】
：
第十八届全国临床肿瘤学大会暨2015年CSCO学术年会
【发表日期】
：
2015年期
其他文献
Background: Concurrent chemoradiation therapy or induction chemotherapy plus surgery were considered as standard treatment to non-small-cell lung cancer (NS
会议
Objective: Lung cancer is the leading cause of cancer-related deaths worldwide with 85% of non-small cell lung cancer (NSCLC) and squamous cell carcinomas (
会议
Objective: Proteinkinase CK2 (also known ascasein kinase) is a highlyconserved seine/threonine protein kinase, which is ubiquitously expressed inmammalian c
会议
Efficacy and safety of nitroglycerin combined with chemotherapy in the elderly patients with advance
Objective: To investigate the efficacy and safety of the treatment of nitroglycerin combined with docetaxel/carboplatin chemotherapy for the elderly patient
会议
18F-FDG PET maximal standardized uptake and serum CEA levels before initial treatment are associated
Objective: Several phase Ⅲ studies demonstrated that, compared with traditional chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (
会议
目的：脑膜癌病临床表现多种多样，缺乏特异性，因此极易漏诊、误诊。现通过收集我院脑膜癌病患者的临床资料，总结临床特征，旨在提高临床医师对本病的认识。方法：通过回顾性分析20
目的：探讨动态监测131I治疗前刺激性甲状腺球蛋白(preablative stimulated thyroglobulin,ps-Tg)变化在伴有远处转移的分化型甲状腺癌(differentiated thyroid cancer,DTC
Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent SCLC:CA209-032 (N
Objective: Patients (pts) with SCLC respond to initial platinum (PLT) based chemotherapy (CT), but rapidly progress.Combined blockade of programmed death-1
会议
目的：淋巴结转移是甲状腺乳头状癌(Papillary Thyroid Carcinoma,PTC)治疗决策中的关键性因素。本研究的目的是寻找包括年龄在内的甲状腺微小乳头状癌(Papillary Thyroid
Survival analysis of non-small cell lung cancer using TKI treatment-- A multi-center retrospective s
Objective: To assess differences in overall survival among patients with NSCLC using TKIs in first or second line treatment and different TKIs.Method: Colle
会议